The Generic Drug Market in 2026: $496 Billion in U.S. Savings on 11.6% of Spend

U.S. patients and the health system saved $496 billion on generic and biosimilar medicines in 2025. That is nearly $30 billion more than the year before. [1] Generics filled 89% of U.S. prescriptions that year, but they took only 11.6% of spending. [1]

That gap is the core of the global generic drug market. It is also the reason policy makers, brand companies, and generic manufacturers now fight over four things: tariffs, FDA review capacity, patent litigation, and biosimilar pricing. This article assembles the current public data on each one. It separates documented facts from our own calculations, and it labels every derived figure.

The Short Answer: What the Generic Drug Market Looks Like in October 2026

Generic drugs are the volume of the U.S. drug market and a small part of its cost. Brand drugs are the opposite. In 2025, brands were 11% of prescriptions and 88.4% of spending. [1]

Four events from the last twelve months matter most for anyone who tracks generic entry:

On April 2, 2026, the President issued Proclamation 11020, which sets Section 232 tariffs on patented pharmaceuticals. Generic drugs and their ingredients are excluded “at this time.” [5][6]
On June 4, 2026, the Supreme Court ruled unanimously for Hikma in Hikma v. Amarin. The ruling protects generic makers that sell under a skinny label. [11]
On August 11, 2026, FDA published a draft GDUFA IV commitment letter that covers fiscal years 2028 to 2032. [22]
In the second quarter of 2026, active U.S. drug shortages rose for the third quarter in a row, to 227. [7]

The Five Findings That Matter

Each finding below stands alone. Calculated figures are marked as analysis.

Generics were 89% of U.S. prescriptions and 11.6% of spending in 2025. [1]
Reported U.S. savings from generics and biosimilars were $496 billion in 2025 and $467 billion in 2024. Analysis: that is a 6.2% increase. [1][2]
FDA approved 689 ANDAs and 250 tentative approvals in fiscal year 2025, while new ANDA receipts fell to 600. [3]
Novartis reported Entresto net sales of $1,253 million in the fourth quarter of 2025, down 43% from $2,180 million, after U.S. generic entry in the third quarter. [13]
Generic drugs and generic APIs are outside the Section 232 pharmaceutical tariffs today, but Commerce must advise within one year on whether to extend them. [5][6]

Definitions: Generic, Biosimilar, ANDA, Loss of Exclusivity, Tentative Approval

Generic drug: a copy of a brand drug that FDA approves through an Abbreviated New Drug Application (ANDA). The applicant must show that the product performs like the brand drug. FDA says the generic must deliver the same amount of active ingredient to the bloodstream in the same time. [26]

Biosimilar: a biological product that FDA approves as highly similar to an approved biologic. FDA lists approved biosimilars in a public table. [15]

Loss of exclusivity (LOE): the date when patent protection or regulatory exclusivity no longer blocks generic or biosimilar entry. Novartis uses the term for Entresto in its annual report. [14]

Tentative approval: FDA has found an ANDA scientifically ready, but a patent or exclusivity still blocks final approval. FDA counts these separately from final approvals in its statistics. [3]

How Big Is the Global Generic Drug Market?

No single authoritative public figure exists for global generic drug sales. Vendor estimates differ by definition, and IQVIA reports total medicine spending, not generics alone. We use both sources and explain their limits.

Vendor Estimate: $430.2 Billion in 2023 to $671.5 Billion in 2030

A market research report titled “Generic Drugs – Global Strategic Business Report” puts the global generic drug market at $430.2 billion in 2023. It projects $671.5 billion by 2030. It states a compound annual growth rate (CAGR) of 5.7% for the period. [24]

The press coverage does not name the publisher. We treat the figure as a vendor estimate, not as a reported statistic.

Why the Stated 5.7% CAGR Does Not Match the Endpoints

Analysis: the two endpoints imply a CAGR of about 6.6% over the seven years from 2023 to 2030. A 5.7% CAGR applied to $430.2 billion for seven years gives about $634 billion, not $671.5 billion. The gap is about $37 billion.

We cannot tell from the coverage whether the source used a different base year, a different compounding rule, or a rounding step. Any writer who cites this market-size projection should quote the endpoints and the stated CAGR together and note that they disagree.

IQVIA: $2.6 Trillion in Total Medicine Spending by 2030

IQVIA expects global medicine spending to exceed $2.6 trillion by 2030, with growth of 5% to 8% per year. [9] The IQVIA Institute published that report on February 11, 2026. [9]

IQVIA also expects total medicine use to approach 4 trillion defined daily doses by the end of the decade. [9] Per capita use growth is 1.9% a year, against 2.7% unadjusted. [9]

Generics are the volume engine inside those totals. The IQVIA pages we read do not give a separate generics figure, so we do not estimate one.

Where Growth Comes From: Pharmerging and Developed Markets

IQVIA projects growth of $155.1 billion through 2030 in high-growth developed countries outside the United States. [9] It projects growth of about $121 billion in pharmerging markets. The report text gives both $121 billion and $120.8 billion for that figure without reconciling them. [9]

The United States and 14 other countries account for 76% of global growth through 2030. [9]

How Much Brand Revenue Faces Patent Expiry?

IQVIA describes a patent expiry wave of nearly $200 billion in brand losses. It calls the wave larger than the one in 2011 and 2012. [10] The page does not give the years that the $200 billion covers, so readers should not attach a date to it.

In the United States, rebates, discounts, and other concessions offset about 46% of invoice value, according to the same IQVIA forecast. [10] Net price growth in the United States is forecast at 4% to 7% a year through 2030. The past five years ran at 9.4%. [10]

How Much Do Generics Save? U.S. Savings Data for 2024 and 2025

The Association for Accessible Medicines (AAM) publishes the most-cited U.S. savings series. AAM is a trade association for generic and biosimilar makers, so readers should treat its figures as industry data. The numbers are still useful, because AAM reports prescription counts and spending in the same release.

“Generics comprised 89% of all prescriptions filled” in 2025, according to the Association for Accessible Medicines. [1]

What the Data Shows: Prescription Share Against Spending Share

Metric	2024 report	2025 report	Source
Reported savings	$467 billion	$496 billion	[2], [1]
Generic share of prescriptions	90% (generic or biosimilar)	89% (generic)	[2], [1]
Generic share of spending	12%	11.6%	[2], [1]
Generic prescriptions	Not in source	4 billion	[1]
Brand prescriptions	Not in source	485 million	[1]
Generic spending	Not in source	$106 billion	[1]
Brand spending	Not in source	$804 billion	[1]

Take care with the 2024 and 2025 comparison. The 2025 press release describes the 90% share as “generic or biosimilar.” [2] The 2026 report describes the 89% share as generics. [1] The wording differs, so a one-point change is not a clean trend.

Cost Per Prescription: Derived Figures

Analysis, using the 2025 data from AAM [1]:

Derived metric	Calculation	Result
Total prescriptions	4,000 million + 485 million	4,485 million
Total spending	$106 billion + $804 billion	$910 billion
Average spend per generic prescription	$106 billion / 4 billion	$26.50
Average spend per brand prescription	$804 billion / 485 million	$1,657.73
Brand-to-generic cost ratio	$1,657.73 / $26.50	62.6 to 1
Reported savings per generic prescription	$496 billion / 4 billion	about $124

These are averages across all products. They hide large differences between a $4 tablet and a $40,000 specialty drug. They also mix definitions: the savings figure includes biosimilars, while the prescription count is for generics. Use the 62.6 to 1 ratio to describe the scale of the gap, not to price any one drug.

Savings Trend: $467 Billion to $496 Billion

Reported savings rose from $467 billion in 2024 to $496 billion in 2025. [2][1] Analysis: that is $29 billion, or 6.2%.

AAM also reports $3.6 trillion in savings over ten years. [1] Analysis: that is an average of $360 billion a year. The 2025 figure is 37.8% above that average, which shows how fast the series grew late in the decade.

Medicare Savings: $166 Billion, or $3,011 Per Beneficiary

AAM reports Medicare savings of $166 billion in 2025, or $3,011 per beneficiary. [1] Analysis: Medicare accounts for 33.5% of the $496 billion total. Dividing $166 billion by $3,011 implies about 55.1 million beneficiaries.

Methodology: How We Built the Derived Figures

This article adds three kinds of original analysis: ratios from AAM data, arithmetic on FDA and Novartis figures, and scenario calculations on tariff exposure. The method is short and reproducible.

Data analyzed: public pages and filings listed in the references. We read each page in October 2026. Where a page gave a “last updated” date, we report it.
Time period: calendar year 2025 for AAM and Novartis data, fiscal year 2025 (October 2024 to September 2025) for FDA Office of Generic Drugs (OGD) data, and the most recent quarter available for shortages.
Record selection: we included a figure only if a named source states it. We did not estimate missing values.
Duplicates: FDA’s calendar-year first-generic count (91) and OGD’s fiscal-year count (92) cover different periods. We report them separately and do not add them.
Calculations: percentages use the stated figures and round to one decimal place. CAGR uses the standard formula, (end / start)^(1 / years) – 1.
Limits: AAM is an industry source. The FDA statistics come through a consulting firm’s summary. The DrugPatentWatch database was not queried for this article.

How Many Generic Drugs Does FDA Approve Each Year?

In fiscal year 2025, FDA approved 689 ANDAs and granted 250 tentative approvals. [3] That is 939 approval actions.

FY2025 Office of Generic Drugs Statistics

Measure	FY2025 value	Source
ANDA approvals	689	[3]
First-time (first generic) approvals, OGD count	92	[3]
First-cycle ANDA approvals	137 (19.9%)	[3]
Tentative approvals	250	[3]
First-cycle tentative approvals	49 (19.6%)	[3]
New ANDA receipts	600 (140 fewer than FY2024)	[3]
ANDAs pending with FDA, September 2025	1,327	[3]
ANDAs awaiting applicant action, September 2025	1,891	[3]

Receipts Fell While Approvals Exceeded Them

Analysis: new ANDA receipts of 600 are 140 fewer than FY2024, which implies 740 receipts a year earlier. That is a drop of 18.9%. FDA approved 689 ANDAs against 600 new receipts, a ratio of 1.15.

The sources we read do not say why submissions fell, so we offer no explanation. Analysis: a smaller intake means a smaller pool of approvals in later years, all else equal.

Only One in Five Approvals Comes on the First Cycle

Analysis: 137 of 689 approvals came in the first cycle. That means 552 approvals, or 80.1%, needed at least one more review cycle. The data does not say what drives the gap, but it shows that most applicants do not clear review on the first try.

2025 First Generic Drug Approvals: Rivaroxaban, Liraglutide, Sitagliptin

FDA lists 91 first generic approvals for calendar year 2025. [4] A first generic is the first approval of a generic version of a brand drug. The list runs from phytonadione injection (Cipla, January 3, 2025) to sitagliptin phosphate tablets (Watson Laboratories, December 30, 2025). [4]

Drug	Applicant	ANDA approval date
Rivaroxaban tablets	Multiple, including Lupin, Taro, Dr. Reddy’s	March 3 and May 14, 2025
Tolvaptan tablets	Lupin	April 23, 2025
Liraglutide injection	Teva	August 27, 2025
Pazopanib tablets	Torrent	September 4, 2025
Axitinib tablets	Apotex	October 30, 2025
Sitagliptin phosphate tablets	Watson Laboratories	December 30, 2025

Source for the table: FDA. [4] FDA notes that approval does not guarantee current market availability. A company can hold an approval and still wait on a patent, a settlement date, or a launch decision. [4]

Rivaroxaban: Nine Approvals on One Day

FDA’s list shows nine rivaroxaban approvals on May 14, 2025, alone. [4] Many applicants can hold approvals for the same product, so one date can open the market to many sellers.

The ANDA Queue: 3,218 Applications in September 2025

Analysis: 1,327 ANDAs were pending with FDA and 1,891 were waiting on the applicant, for a total of 3,218. [3] FDA held 41.2% of that queue. Applicants held 58.8%.

Analysis: 1,327 pending applications equal about 1.4 years of FY2025 action volume (939 approvals and tentative approvals). This is a rough guide only, because some pending files will end in a complete response letter and not an approval.

What Is the Hatch-Waxman Framework and Why Does It Still Drive Generic Entry?

The Hatch-Waxman Act of 1984 set bioequivalence as the basis for approving generic copies. FDA also says the law let generic companies challenge patents in court before marketing. [26]

Two mechanisms in 21 U.S.C. § 355(j) shape almost every launch date. [27]

Paragraph IV Certification and the 30-Month Stay

An ANDA applicant that believes a listed patent is invalid or not infringed files a Paragraph IV certification. The brand company can sue. If it sues within the statutory window, FDA cannot give final approval for up to 30 months, unless a court rules earlier. [27]

The brand company therefore controls the timing of the dispute. The generic company controls the date of the challenge.

180-Day Exclusivity for the First Filer

The first applicant to file a substantially complete ANDA with a Paragraph IV certification can earn 180 days of generic exclusivity. During that time FDA cannot approve later ANDAs for the same product. [27]

Hikma v. Amarin: What Skinny Labels Look Like After the Supreme Court Decision

On June 4, 2026, the Supreme Court unanimously reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma induced infringement. Justice Jackson wrote the opinion. [11]

Facts of the Case: Vascepa and the Carve-Out

Amarin sells Vascepa (icosapent ethyl). Vascepa received FDA approval for a cardiovascular indication in 2019. Hikma’s generic received approval in 2020 for the unpatented severe hypertriglyceridemia indication only. This type of label is called a skinny label. [12]

Amarin sued. The district court dismissed the case at the pleading stage. The Federal Circuit revived it and found it “at least plausible that a physician could read” Hikma’s statements as encouraging infringement. [12]

What the Court Held

AIPLA reports that the Court framed the key question as “whether the manufacturer itself took affirmative steps to promote or encourage infringement.” [11] The Court found that Hikma’s label, website statements, and press releases did not meet that test. [11]

The Court also rejected the Federal Circuit’s focus on how health care providers might read the statements. Speculation about third-party interpretation is not enough. [11] The Court applied the Twombly and Iqbal pleading standards. [11]

What This Means for Generic Manufacturers

A properly drafted skinny label alone is unlikely to support an inducement claim. [12] Generic makers can pursue carve-outs for products where a method-of-use patent covers one indication and not others.

Conduct beyond the label still carries risk. The commentary we read notes that liability can arise if other conduct clearly encourages a patented use. [12]

What This Means for Brand Manufacturers

Brand companies should check how patent claim scope lines up with the FDA-approved indications. A gap between the two can open a skinny-label path for generics. [12] The decision also raises the pleading burden for inducement suits, which makes early dismissal more likely when a complaint rests on label language and standard equivalence statements. [11]

Case Study: Entresto Generic Entry and Novartis Revenue

Novartis lost U.S. market exclusivity for Entresto in July 2025. [14] The company reports that Entresto sales declined because of generic entry in the United States in the third quarter of 2025. [13]

The Numbers: Q4 2025 Against Q4 2024

Period	Entresto net sales	Change	Source
Q4 2024	$2,180 million	Base	[13]
Q4 2025	$1,253 million	Down 43% USD, down 45% constant currency	[13]
FY 2024	$7,822 million	Base	[13]
FY 2025	$7,748 million	Down 1% USD, down 2% constant currency	[13]

Novartis states that revenue deduction adjustments affected the fourth quarter. Excluding those adjustments, Q4 sales fell 32% in USD and 34% in constant currency. [13] At group level, the U.S. adjustments cost 3 percentage points of Q4 growth, mainly from Entresto and Promacta. [13]

Entresto kept growing outside the United States. Novartis says it is approved for heart failure globally and for hypertension in China and Japan. [13] Novartis also reports litigation with a generic manufacturer to protect its Entresto IP rights. [13]

Regulatory data protection for Entresto in Europe expires in November 2026. [14] That date is the next documented exposure point outside the United States.

Run-Rate Scenario: What the Fourth Quarter Implies

Analysis: the first three quarters of 2025 sum to $6,495 million ($7,748 million minus $1,253 million), an average of $2,165 million a quarter. Q4 sales were 42.1% below that average. Entresto’s fourth quarter was 16.2% of its full-year sales.

Scenario, not a forecast: if Q4 sales held for four quarters, annual sales would be $5,012 million. That is $2,736 million, or 35.3%, below the 2025 total. The scenario ignores ex-U.S. growth, further U.S. share loss, and the revenue deduction adjustments that Novartis flags. It shows only how large the 2025 full-year number looks compared with the exit rate.

Case Study: Eliquis and the Patent Timeline to April 2028

The Federal Circuit affirmed a Delaware district court ruling in September 2021 and upheld two Eliquis patents: the composition of matter patent and a formulation patent. [18] Bristol Myers Squibb and Pfizer reported that U.S. exclusivity was expected to last until April 1, 2028. [18]

Before that ruling, analysts expected generic entry between 2026 and 2031. [18] The challengers that went to court included Sigmapharm, Sunshine Lake Pharma, Hec Pharm, and Unichem. Other generic makers had settled. [18]

Analysis: from the September 2021 ruling to April 1, 2028 is about 6.6 years. Approved generics cannot launch before the settlement terms or the patents allow it. [18] This is the pattern that FDA’s approval list shows for rivaroxaban in 2025: the approval and the launch are two separate events.

The Eliquis source is from 2021. Readers who need current litigation status should check docket records and the Orange Book listing before they act on the April 2028 date.

Biosimilars vs. Generics: Where Is Price Pressure Strongest Now?

Generics compete on price for small molecules. Biosimilars compete on price for biologics, and they also compete on formulary access. The Stelara market in 2025 is the clearest recent example.

89 FDA-Approved Biosimilars as of October 2026

FDA’s biosimilar table was current as of October 5, 2026, and it contains 89 rows. Some rows list two product names. [15] Morgan Lewis also reports 89 approved U.S. biosimilars in its review of the second quarter of 2026. [16]

The recent approvals in that review include rituximab-cdxx (Zimrixby), insulin aspart-fsan (Garzulys), ranibizumab-hkdz (Ranluspec), golimumab-sldi (Immgolis), pegfilgrastim-pccg (Ennumo), insulin glargine-aldy (Langlara), and denosumab-adet (Ponlimsi). [16]

Stelara Biosimilar Price War: How the 2025 Launches Worked

Drug Channels describes the Stelara (ustekinumab) launches as the biggest biosimilar launches for pharmacy benefits in 2025. [17] The post counts nine biosimilar versions and one unbranded Johnson & Johnson product. [17]

Biosimilar list prices ran from 5% to 90% below Stelara’s list price. [17] Amgen’s Wezlana was approved in October 2023 as the first interchangeable Stelara biosimilar. Its interchangeable exclusivity ended in April 2025, so all approved biosimilars are now interchangeable. [17] Four of the nine biosimilars sell through PBM-affiliated private-label businesses. [17]

PBM Private Labels and Formulary Exclusions

PBM	Documented move	Source
CVS Caremark (Cordavis)	Lists Stelara plus three biosimilars at 86% and 90% below the reference price	[17]
Express Scripts (Quallent)	July 2025 exclusions include Stelara; an unbranded Quallent product at 46% below reference; two branded biosimilars at 86% and 90% below	[17]
Optum Rx (Nuvaila)	From July 1, 2025, excluded Stelara from Premium Value and Premium Standard formularies in favor of Wezlana for Nuvaila	[17]
Navitus	Excluded Stelara in favor of Teva’s unbranded ustekinumab-aekn, Steqeyma, and Yesintek	[17]

The Drug Channels post could not explain why the Quallent discount is 46%, when Evernorth had announced 90%. [17] We do not guess at a reason.

Medicare Negotiation Adds a Second Price Signal

Stelara is one of 10 drugs selected for Inflation Reduction Act negotiation. Its maximum fair price for 2026 is 66% below its 2023 list price. [17] CMS said it will watch whether meaningful biosimilar competition exists, including whether biosimilars are consistently available through the supply chain. [17] IQVIA notes that the first IRA negotiated prices took effect in 2026. [10]

Are Generic Drugs Covered by the Section 232 Pharmaceutical Tariffs?

No, not today. The Federal Register notice of September 23, 2026 states: “At this time, Section 232 Pharmaceutical Tariffs do not apply to generic pharmaceutical products and associated ingredients.” [6]

What the Federal Register Says

Proclamation 11020, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States,” is dated April 2, 2026. [6] The tariffs cover patented drugs and biologics that have a valid, unexpired U.S. patent and a listing in the Orange Book or Purple Book, along with their APIs. [5]

The notice defines a generic pharmaceutical article to include a drug product or biosimilar approved under a qualifying application, and the active pharmaceutical ingredient used in such a product. [6] The notice also adds unpatented animal health products to that definition. [6]

Item	Documented detail	Source
General rate on patented pharmaceuticals	100%	[5]
Reduced rate	15% for Japan, EU member states, South Korea, Switzerland, and Liechtenstein	[5]
Start date, Annex III companies	July 31, 2026	[6]
Start date, all other companies	September 29, 2026	[6]
Generics, biosimilars, generic APIs	Excluded “at this time”	[5], [6]
Commerce advice on extending to generics	Due within one year of the proclamation	[5]

The law firm summary and the Federal Register differ on which companies get the later start date. We follow the Federal Register. [5][6] Analysis: one year from April 2, 2026 is April 2, 2027. That is the outer date for Commerce’s advice, so generic makers should treat the first half of 2027 as the decision window.

Scenario Analysis: What an Extension Could Cost Indian Exporters

India’s pharmaceutical exports to the United States were $9.7 billion in 2025, which is 38% of India’s global pharmaceutical exports of $25.8 billion. [19] Around 90% of India’s pharmaceutical exports to the United States are generics. [19]

Analysis: 90% of $9.7 billion is about $8.7 billion. Analysis: $9.7 billion divided by $25.8 billion is 37.6%. The 90% figure describes the product mix of Indian exports, not India’s share of U.S. generic supply, and the source says so. [19]

Hypothetical duty rate	Duty on about $8.73 billion of generic exports
10%	about $0.87 billion
25%	about $2.18 billion
100%	about $8.73 billion

This is arithmetic, not a forecast. It assumes constant volume, that export value equals customs value, and that the 90% share applies to the full year. It does not model who pays the duty. No document we read proposes any of these rates for generics.

The Global Trade Research Initiative’s Ajay Srivastava has flagged uncertainty if tariffs extend to generics. [19]

Supply Chain: India, China Volume-Based Procurement, and the Drug Shortage Count

India’s Export Growth, 2021 to 2025

India’s pharmaceutical exports to the United States were $6.62 billion in 2021, $8.87 billion in 2024, and $9.7 billion in 2025. [19] Analysis: that is growth of 46.5% over four years, a CAGR of about 10.0%, and 9.4% growth from 2024 to 2025.

China’s Volume-Based Procurement: 435 Drug Types in Ten Rounds

China began volume-based procurement in 2018 with a pilot in 11 cities, then expanded it nationwide. Ten rounds covered 435 drug types. [25] Rounds 1 to 9 cut prices by about 50% on average, with some products down more than 90%. Round 10, in December 2024, cut prices by more than 70% on average. [25]

Domestic generics won 96% of winning bids in rounds 1 to 9. [25] NHSA data show the market share of drugs that passed equivalence evaluation rose from about 50% before the policy to about 95% after it. [25] The Stanford analysis also records public concern that very low bids could weaken manufacturers’ incentive to maintain quality. [25]

Drug Shortages: From 323 to 227

Period	Active U.S. shortages (ASHP)	Source
Q1 2024	323 (all-time high)	[8]
Q1 2026	223 (second consecutive increase)	[8]
Q2 2026	227 (third consecutive increase)	[7]

Analysis: shortages fell 31.0% from Q1 2024 to Q1 2026. They rose 1.8% from Q1 to Q2 2026. The Q2 2026 count is still 29.7% below the peak.

The count comes from the American Society of Health-System Pharmacists and the University of Utah Drug Information Service. [7] We do not attribute the shortages to any one cause, because the sources we read do not do so.

GDUFA IV: What FDA Proposes for Fiscal Years 2028 to 2032

FDA published the draft GDUFA IV commitment letter in the Federal Register on August 11, 2026. It covers fiscal years 2028 to 2032. [22] GDUFA III expires on September 30, 2027, so Congress must reauthorize the program before that date. [22]

FDA held a public meeting on September 17, 2026. Written comments are due October 17, 2026. [22]

Onshoring Incentives in the Draft

FDA proposes to raise the foreign facility fee differential from $15,000 to $25,000 from fiscal year 2028. Foreign fees have not changed since GDUFA began in fiscal year 2013, and industry opposed the increase. [21] FDA also proposes to waive ANDA submission fees for domestic applicants whose applications list only U.S. facilities for the finished dosage form and the API. That waiver needs a statutory change. [21][22]

Sponsors could request pre-submission inspections of domestic facilities. FDA commits to act on at least 90% of eligible requests within 30 days. [22]

The draft follows a pilot that FDA announced on October 7, 2025. The pilot gives ANDA applicants priority review when the finished dosage form or API is made in the United States. [23] The sources we read give no target review time for the pilot.

Review Process Changes

FDA proposes four meeting types (Type 30, 60, 90, and 120) and a six-month goal date extension when it expects to miss a goal date by more than 60 days. [22] It would also publish a Maximum Daily Dose database with at least 500 values for reference listed drugs by the end of fiscal year 2028. [21]

Semaglutide: Patent Expiries in India, China, and Canada in 2026

Asia IP Law reports that key semaglutide patents in India, China, and Canada expired in 2026. For Canada it also refers to the expiry of data protection. [28] The article gives no specific expiry dates and names no confirmed filers. [28]

It describes Dr. Reddy’s, Sun Pharma, and Lupin as frequently mentioned likely entrants in India. They are not confirmed filers. Timing will vary by country, based on regulatory review and any remaining patent disputes. [28]

These expiries do not change U.S. status. FDA’s 2025 list does include a first generic of liraglutide (Teva, August 27, 2025), which is an older GLP-1 molecule. [4]

Original Framework: Four Types of Generic Market Pressure

This is our own classification, not an industry standard. We built it from the cases above to help readers sort exposure by mechanism.

Type	Main driver	Documented example	Source
1. Litigation-gated	Court outcome or settlement sets entry date	Eliquis, April 1, 2028 expected exclusivity	[18]
2. Label-gated	Carve-out of patented indications	Hikma generic for Vascepa	[11], [12]
3. Formulary-gated	PBM private labels and exclusions decide share	Stelara biosimilars, 2025	[17]
4. Procurement-gated	Government tender sets price	China VBP, rounds 1 to 10	[25]

One drug can sit in more than one type. Entresto is litigation-gated in its history, and it now faces open-market price competition. A reader can use the table to ask a plain question: who sets the entry date, and who sets the price after entry?

What This Means for Different Players in the Generic Market

What This Means for Generic Manufacturers

FDA’s ANDA receipts fell while approvals ran ahead of them. [3] Analysis: 80.1% of approvals needed more than one review cycle, so file quality has a direct effect on time to market.

The GDUFA IV draft shifts costs toward foreign facilities and away from domestic applicants. [21] Firms with Indian or Chinese sites should model the $25,000 fee differential from fiscal year 2028.

What This Means for Brand Manufacturers

Entresto shows the shape of the loss: flat full-year sales and a 43% drop in the next quarter. [13] Brand teams should plan for the exit rate, not the annual total.

After Hikma v. Amarin, patent claims and approved indications need to line up, since a gap can give generics a path to market. [12]

What This Means for Payers and Pharmacy Benefit Managers

PBM-affiliated private labels sold four of the nine Stelara biosimilars. [17] That gives PBMs a direct financial stake in which version wins formulary position. Payers that sign contracts with PBMs should ask which product the PBM owns.

What This Means for Biosimilar Developers

With 89 biosimilars approved, approval alone no longer sets a product apart. [15][16] Access to a PBM formulary and the list-price strategy decide volume. [17]

How DrugPatentWatch Fits Into Generic Market Research

DrugPatentWatch is a database that analysts use for patent, exclusivity, and generic-entry research. Its own published guidance says the platform aggregates Orange Book data, exclusivity period calculations, Paragraph IV filing histories, and 180-day exclusivity status. It also describes ANDA tracking data that can help find first-to-file opportunities. [20]

The figures in this article come from the cited primary and secondary sources. They do not come from a DrugPatentWatch query. Use DrugPatentWatch to check the patent and exclusivity status of a specific drug, and use FDA, court, and company filings as the evidence of record.

Key Takeaways

Generics were 89% of U.S. prescriptions and 11.6% of spending in 2025. [1]
Reported U.S. savings were $496 billion in 2025, up from $467 billion. Analysis: growth of 6.2%. [1][2]
FDA approved 689 ANDAs and 250 tentative approvals in fiscal year 2025. New ANDA receipts were 600, which is 140 fewer than in fiscal year 2024. [3]
Entresto Q4 2025 net sales fell 43% after U.S. generic entry. [13]
The Supreme Court ruled unanimously for Hikma on June 4, 2026. [11]
Section 232 pharmaceutical tariffs exclude generics “at this time.” Commerce advice on extension is due within one year of April 2, 2026. [5][6]
Active U.S. drug shortages were 227 in Q2 2026, against a peak of 323 in Q1 2024. [7][8]
FDA lists 89 approved biosimilars as of October 5, 2026. [15]
The GDUFA IV draft covers fiscal years 2028 to 2032 and raises the foreign facility fee differential to $25,000. [21][22]

FAQ: Generic Drug Market Questions

How much of the U.S. drug market do generics hold?

Generics held 89% of prescriptions and 11.6% of spending in 2025. [1]

How much did generics and biosimilars save the U.S. in 2025?

AAM reports $496 billion in 2025 savings and $3.6 trillion over ten years. [1]

How many generic drugs did FDA approve in fiscal year 2025?

FDA approved 689 ANDAs, and it granted 250 tentative approvals. [3]

How many first generics did FDA approve in 2025?

FDA’s calendar-year 2025 list has 91 first generic approvals. [4]

Do the Section 232 tariffs apply to generic drugs?

No. The September 23, 2026 Federal Register notice says they do not apply to generic pharmaceutical products and associated ingredients “at this time.” [6]